PAHC
Price
$34.69
Change
+$0.32 (+0.93%)
Updated
May 18, 02:36 PM (EDT)
Capitalization
1.39B
107 days until earnings call
Intraday BUY SELL Signals
ZTS
Price
$77.42
Change
+$3.21 (+4.32%)
Updated
May 18, 02:45 PM (EDT)
Capitalization
31.12B
85 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PAHC vs ZTS

Header iconPAHC vs ZTS Comparison
Open Charts PAHC vs ZTSBanner chart's image
PAHC vs ZTS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
PAHC vs. ZTS commentary
May 18, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PAHC is a Hold and ZTS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 18, 2026
Stock price -- (PAHC: $34.37 vs. ZTS: $74.22)
Brand notoriety: PAHC: Not notable vs. ZTS: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: PAHC: 132% vs. ZTS: 162%
Market capitalization -- PAHC: $1.39B vs. ZTS: $31.12B
PAHC [@Pharmaceuticals: Generic] is valued at $1.39B. ZTS’s [@Pharmaceuticals: Generic] market capitalization is $31.12B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PAHC’s FA Score shows that 2 FA rating(s) are green whileZTS’s FA Score has 2 green FA rating(s).

  • PAHC’s FA Score: 2 green, 3 red.
  • ZTS’s FA Score: 2 green, 3 red.
According to our system of comparison, both PAHC and ZTS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PAHC’s TA Score shows that 4 TA indicator(s) are bullish while ZTS’s TA Score has 5 bullish TA indicator(s).

  • PAHC’s TA Score: 4 bullish, 6 bearish.
  • ZTS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ZTS is a better buy in the short-term than PAHC.

Price Growth

PAHC (@Pharmaceuticals: Generic) experienced а -14.08% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was -10.39% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.13%. For the same industry, the average monthly price growth was -1.41%, and the average quarterly price growth was +6.91%.

Reported Earning Dates

PAHC is expected to report earnings on Sep 02, 2026.

ZTS is expected to report earnings on Aug 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-2.13% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZTS($31.1B) has a higher market cap than PAHC($1.39B). PAHC has higher P/E ratio than ZTS: PAHC (14.75) vs ZTS (12.17). PAHC YTD gains are higher at: -7.792 vs. ZTS (-40.501). ZTS has higher annual earnings (EBITDA): 4.06B vs. PAHC (222M). ZTS has more cash in the bank: 1.94B vs. PAHC (77.5M). PAHC has less debt than ZTS: PAHC (787M) vs ZTS (9.24B). ZTS has higher revenues than PAHC: ZTS (9.53B) vs PAHC (1.5B).
PAHCZTSPAHC / ZTS
Capitalization1.39B31.1B4%
EBITDA222M4.06B5%
Gain YTD-7.792-40.50119%
P/E Ratio14.7512.17121%
Revenue1.5B9.53B16%
Total Cash77.5M1.94B4%
Total Debt787M9.24B9%
FUNDAMENTALS RATINGS
PAHC vs ZTS: Fundamental Ratings
PAHC
ZTS
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
16
Undervalued
PROFIT vs RISK RATING
1..100
70100
SMR RATING
1..100
3217
PRICE GROWTH RATING
1..100
6565
P/E GROWTH RATING
1..100
9496
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZTS's Valuation (16) in the Pharmaceuticals Generic industry is in the same range as PAHC (29) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew similarly to PAHC’s over the last 12 months.

PAHC's Profit vs Risk Rating (70) in the Pharmaceuticals Major industry is in the same range as ZTS (100) in the Pharmaceuticals Generic industry. This means that PAHC’s stock grew similarly to ZTS’s over the last 12 months.

ZTS's SMR Rating (17) in the Pharmaceuticals Generic industry is in the same range as PAHC (32) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew similarly to PAHC’s over the last 12 months.

ZTS's Price Growth Rating (65) in the Pharmaceuticals Generic industry is in the same range as PAHC (65) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew similarly to PAHC’s over the last 12 months.

PAHC's P/E Growth Rating (94) in the Pharmaceuticals Major industry is in the same range as ZTS (96) in the Pharmaceuticals Generic industry. This means that PAHC’s stock grew similarly to ZTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PAHCZTS
RSI
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
54%
Momentum
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 4 days ago
69%
MACD
ODDS (%)
Bearish Trend 4 days ago
73%
Bearish Trend 4 days ago
62%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
73%
Bearish Trend 4 days ago
61%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
70%
Bearish Trend 4 days ago
63%
Advances
ODDS (%)
Bullish Trend 13 days ago
74%
Bullish Trend 22 days ago
51%
Declines
ODDS (%)
Bearish Trend 8 days ago
75%
Bearish Trend 8 days ago
58%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
62%
Aroon
ODDS (%)
Bearish Trend 4 days ago
66%
Bullish Trend 4 days ago
42%
View a ticker or compare two or three
Interact to see
Advertisement
PAHC
Daily Signal:
Gain/Loss:
ZTS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AAIIX7.14-0.04
-0.56%
Ancora Income I
MVGMX17.71-0.17
-0.95%
MFS Low Volatility Global Equity R4
JDESX51.33-0.62
-1.19%
JPMorgan US Research Enhanced Equity I
PRESX25.02-0.48
-1.88%
T. Rowe Price European Stock
BDOKX14.25-0.34
-2.33%
iShares MSCI Total Intl Idx K

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with ZTS. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then ZTS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
-4.92%
ZTS - PAHC
59%
Loosely correlated
-1.67%
ELAN - PAHC
47%
Loosely correlated
-8.23%
AMRX - PAHC
32%
Poorly correlated
-2.45%
COLL - PAHC
31%
Poorly correlated
-3.01%
VTRS - PAHC
29%
Poorly correlated
-4.52%
More

ZTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with PAHC. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZTS
1D Price
Change %
ZTS100%
-1.67%
PAHC - ZTS
59%
Loosely correlated
-4.92%
ELAN - ZTS
48%
Loosely correlated
-8.23%
VTRS - ZTS
36%
Loosely correlated
-4.52%
PRGO - ZTS
34%
Loosely correlated
-2.12%
SNDL - ZTS
33%
Loosely correlated
-2.05%
More